NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$329.83▼$329.8350-Day Range$313.97▼$329.8352-Week Range$158.38▼$329.99Volume5 shsAverage Volume832,048 shsMarket Capitalization$12.58 billionP/E RatioN/ADividend YieldN/APrice Target$299.67 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends Get Karuna Therapeutics alerts: Email Address Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Karuna Therapeutics Stock (NASDAQ:KRTX)Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. KRTX Stock News HeadlinesApril 26, 2024 | investing.comS&P 500 Q1 earnings estimated growth improves; stocks up for weekApril 25, 2024 | investing.comBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planSeptember 8, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… April 22, 2024 | bizjournals.comAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotechApril 9, 2024 | msn.comSeaport Therapeutics has $100 million to develop new ways to treat mental disordersMarch 15, 2024 | finance.yahoo.comLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermMarch 15, 2024 | ca.finance.yahoo.comKRTX May 2024 210.000 callMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)September 8, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… March 4, 2024 | finance.yahoo.comBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionFebruary 26, 2024 | msn.comKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbFebruary 23, 2024 | benzinga.com1KRTX : Karuna Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comKaruna Therapeutics GAAP EPS of -$3.01 misses by $0.29February 22, 2024 | finance.yahoo.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 22, 2024 | businesswire.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 21, 2024 | seekingalpha.comBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessFebruary 18, 2024 | seekingalpha.comKaruna Therapeutics: Getting Sold ShortFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 320.000 callSee More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year FoundedN/APrice Target and Rating Average Stock Price Target$299.67 High Stock Price Target$330.00 Low Stock Price Target$225.00 Potential Upside/Downside-9.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-433,680,000.00 Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$654,000.00 Price / Sales19,239.07 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,148,000Free Float33,157,000Market Cap$12.58 billion OptionableOptionable Beta1.18 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Andrew Craig Miller Ph.D. (Age 42)Founder and President of Research & Development Comp: $835.4kDr. Stephen K. Brannan (Age 68)Chief Medical Officer Comp: $751.75kMr. William Meury (Age 56)President, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Alexis SmithVice President of Corporate Affairs & Investor RelationsMs. Mia Kelley J.D.General CounselMr. Frank TruslowSenior Vice President of Corporate DevelopmentMr. Jonathan RosinChief Human Resources OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorDr. Ronald N. Marcus M.D. (Age 66)Senior Vice President of Medical More ExecutivesKey CompetitorsGlobal Blood TherapeuticsNASDAQ:GBTTaro Pharmaceutical IndustriesNYSE:TAROOPKO HealthNASDAQ:OPKADC TherapeuticsNYSE:ADCTTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsidersStephen K BrannanSold 5,000 sharesTotal: $1.59 M ($318.34/share)Stephen K BrannanSold 5,000 sharesTotal: $1.58 M ($316.13/share)Stephen K BrannanSold 15,000 sharesTotal: $4.75 M ($316.81/share)Stephen K BrannanSold 10,000 sharesTotal: $2.02 M ($202.37/share)Stephen K BrannanSold 5,000 sharesTotal: $889,250.00 ($177.85/share)View All Insider Transactions KRTX Stock Analysis - Frequently Asked Questions How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, February, 22nd. The company reported ($3.01) EPS for the quarter, missing the consensus estimate of ($2.65) by $0.36. The firm's revenue was down 100.0% compared to the same quarter last year. When did Karuna Therapeutics IPO? Karuna Therapeutics (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA) and Johnson & Johnson (JNJ). This page (NASDAQ:KRTX) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karuna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.